Julian Schwärzler

TL;DR: It is reported that dietary polyunsaturated fatty acids trigger intestinal inflammation resembling aspects of Crohn’s disease, which is restricted by glutathione peroxidase 4 in the intestinal epithelium.

TL;DR: Experimental and clinical evidence supports a role of metabolic perturbation in the development of gut inflammation in inflammatory bowel disease (IBD), outlining key concepts and highlighting the links between metabolism and inflammation in IBD.

TL;DR: Evidence is provided for the concept of PUFA-induced metabolic gut inflammation which may worsen the course of human CD, and provides a basis for targeted nutritional therapy.

TL;DR: Experimental and clinical approaches used to untie the intricate pancreas-microbiota cross talk are summarized and future advances will allow clinicians to manipulate the intestinal microbiota and guide patient management in pancreatic diseases.

TL;DR: It is hypothesized that the immunomodulator dimethyl‐fumarate (DMF), which is approved for the treatment of human inflammatory conditions such as multiple sclerosis or psoriasis, ameliorates the course of experimental ALD.